ABSTRACT
INTRODUCTION
Diabetes mellitus (DM) is a complex disease characterized by chronic hyperglycaemia, metabolic abnormalities and long term macro-and microvascular complications involving the blood vessels, eyes, kidneys and nerves. These complications are mainly due to hyperglycaemia and are responsible for the majority of morbidity and mortality associated with DM (1) .
Fasting blood glucose (FBG), postprandial blood glucose (PBG) and haemoglobin A1c (HbA1c) are widely used to monitor glycometabolic control in patients with DM. Haemoglobin A1c is a more useful marker to determine mean blood glucose levels over a long time period (2, 3) .
Diabetes mellitus is suggested as a prothrombotic state because platelet function and morphology are usually altered in these patients (4, 5) . Mean platelet volume (MPV) is considered one of the important markers of platelet activation. It can be easily measured as part of whole blood count (6, 7) . Whether MPV is related to glycometabolic markers such as FBG, PBG and HbA1c is unclear. There is a range of different data about this issue in the literature (8) (9) (10) (11) (12) (13) . Also, the relationship between MPV and diabetic microvascular complications remains to be clarified. Thus, the aim of this study was (i) to compare MPV between Type 2 diabetic patients and a non-diabetic control group, (ii) to analyse the correlations between MPV and FBG, PBG, HbA1c and other parameters in diabetic patients, (iii) to evaluate MPV according to HbA1c levels in the diabetic group, and (iv) to assess the difference in MPV between patients with and without microvascular complications.
SUBJECTS AND METHODS Patients
This was a retrospective study conducted on 60 (40 female, 20 male) Type 2 diabetic patients and 50 age-and sexmatched non-diabetic controls. The patient and control groups were recruited from the outpatient clinic at the Department of Internal Medicine in Duzce University School of Medicine between August 2008 and November 2008. The control group was obtained from individuals without DM, as identified from their medical records. Patients were excluded if they had Type 1 or other types of DM, thrombotic or haematologic disorders, any medication affecting platelet function, serious cardiovascular, hepatic and renal disease, haemoglobin < 12.5 g/dL in men and < 11.5 g/dL in women, or a history of smoking and drinking. Controls were excluded if they had any types of DM and/or any exclusion criteria for the patient group. Type 2 DM was diagnosed according to the American Diabetes Association criteria (14) .
Demographic and clinical characteristics of patients and controls were recorded from their medical records: age, gender, height, weight, systolic and diastolic blood pressure (BP), duration of disease and other medical history, medication, and laboratory data. The treatment of patients was as follows: 65% oral anti-diabetic drugs, 33% insulin, 28% angiotensin-converting enzyme inhibitor, 15% calcium channel blockers and 15% statin.
Laboratory
All biochemical, whole blood count and urine tests were performed at the Biochemistry Laboratory of Duzce University Medical Faculty. Blood samples were taken after an 8-12 hour period of fasting, in a sitting position. Samples for MPV and platelets collected using EDTA as anticoagulant were analysed on a Sysmex-xt-2000i auto-analyser. Biochemical tests were done following the manufacturer's recommendations on a Roche/Hitachi Diagnostic Systems cobas c 501. Glucose level was measured by the oxidase method (15) . Haemoglobin A1c level was analysed by immunoturbidimetric inhibition method (16) . Total cholesterol, triglyceride and high density lipoprotein (HDL) cholesterol were measured by commercial enzymatic methods (17) (18) (19) . Low density lipoprotein (LDL) cholesterol was calculated using Friedewald's formula (20) .
Serum and urine creatinine levels were determined by the Jaffee method (21) . Urinary albumin excretion was measured with the turbidimetric method (22) . Urine albumin creatinine ratio (UACR) was calculated as mg/g in the morning first void urine.
Body mass index (BMI) was calculated as weight in kilogram by height in meters squared. Blood pressure was measured by a cuff-type sphygmomanometer device. Korotkoff's first sound was recorded as systolic BP and Korotkoff's fifth sound was recorded as diastolic BP.
HbA1c (p = 0.03 y p < 0.001, respectivamente). También se observó una correlación negativa con el conteo de plaquetas (p < 0.001). El volumen medio de plaquetas en los pacientes con
Diabetic retinopathy was diagnosed as follows: at least two microaneurysms and/or retinal haemorrhage, and findings of retinal damage (23) . Diabetic nephropathy was defined as UACR between 30 and 300 mg/g in at least two of three analyses (24) . Diabetic neuropathy was diagnosed according to the symptoms and physical examination of patients after excluding other reasons for neuropathy.
Statistical analysis
All analyses were performed using Statistical Package for Social Sciences (SPSS) version 15.0 for Windows. Data are expressed as mean ± standard deviation. One-sample Kolmogorov-Smirnov test was performed to prove the data distributions. Numerical variables were compared by the t-test or Mann-Whitney U test. Bivariate correlation analyses were made using the Pearson correlation test. Categorical variables were analysed by Chi-square test. Probability values were two-tailed, and a p-value of less than 0.05 was considered significant.
RESULTS
Clinical and demographic characteristics were similar in the patient and control groups except for MPV (Table 1) . Mean platelet volume level was found to positively correlate with FBG and HbA1c levels. Mean platelet volume level was negatively related to platelet count. There was no significant correlation between MPV and PBG, duration of DM, lipid profile, creatinine, systolic and diastolic BP (Table 2) .
When the patient group was divided into two groups according to their HbA1c levels (group 1: HbA1c ≤ 7 and group 2: HbA1c > 7), MPV levels in group 2 were higher than in group 1 (p < 0.001). However, platelet count was lower in group 2 than group 1 ( Table 3 ). The ratio of diabetic microvascular complications including nephropathy, neuropathy and retinopathy was higher in group 2 than in group 1 (60% vs 23%; 50% vs 23%; 57% vs 23%; p < 0.001, p = 0.03 and p = 0.01, respectively).
Dindar et al Relationship between Mean Platelet Volume, HbA1c and Retinopathy Diabetic microvascular complications were present as follows: nephropathy in 25 patients (42%), neuropathy in 22 patients (37%) and retinopathy in 24 patients (40%). Mean platelet volume level was significantly increased in patients with diabetic retinopathy compared to those without retinopathy (p = 0.04). Mean platelet volume was higher in patients with nephropathy and neuropathy, but not statistically significant (p = 0.34 and p = 0.09, respectively) [ Table 4 ]. status alone, and (ii) the potential role of platelets in the development of diabetic vascular complications may be attenuated by a decrease in MPV. An inverse relationship is described between MPV and platelet count, reflecting the tendency to keep haemostasis by preserving a constant platelet mass (29) . We found that MPV was inversely related to platelet count. Moreover, platelet count in patients with HbA1c > 7% was significantly lower than those with HbA1c ≤ 7%. This result supports the opinion that an enhanced destruction and osmotic swelling of platelets may affect this relationship (30) .
Hypertension is known as one of the diseases enhancing platelet activity. Mean platelet volume is usually increased in patients with elevated systolic BP and target organ damage (31) . Mean platelet volume is not associated with systolic and diastolic BP in the present study. It has been reported that BP control is related to decreasing MPV (30) . Renin-angiotensin system blockade with medication and a well-controlled BP in our patients may be a reason for this result.
Micro-and macrovascular complications are often seen in DM and represent the main causes of morbidity and mortality, which are closely associated with glycaemic control (32) . Mean platelet volume is usually established to associate with macrovascular complications such as myocardial infarction and restenosis after percutaneous coronary intervention (26) .
There are different results about the relationship between MPV and diabetic microvascular complications in the literature. Mean platelet volume was not found to be different between patients with and without microvascular complications (12, 13) . However, it was shown that MPV is significantly related to diabetic nephropathy in other studies (8, 9) . Furthermore, MPV was determined to be associated with retinal neovascularization of diabetic retinopathy (33) .
We found that MPV in patients with diabetic retinopathy was significantly higher compared to those without diabetic retinopathy. Moreover, MPV is higher in patients with nephropathy and neuropathy than those without nephropathy and neuropathy, but not statistically significant. This result has shown that MPV may be a target to prevent diabetic retinopathy.
Despite several important findings in the present study, it has some limitations including its relatively small sample size and retrospective design. The difference in MPV between patients with and without neuropathy was close to the significance level. This difference might be found statistically significant in a larger sample size. Furthermore, more useful information about the relationship between MPV and diabetic microvascular complications would have been provided if the study had been designed prospectively.
In conclusion, this study has shown that (i) MPV is increased in diabetic patients, (ii) it is associated with the degree of glycaemic control and (iii) MPV is increased in patients with diabetic retinopathy. However, further prospec- 
DISCUSSION
This study suggests that MPV is increased and associated with poor glycometabolic control and it may be related to retinopathy in Type 2 diabetic patients. Platelet hyper-reactivity is known as a contributing factor to the prothrombotic condition in diabetic patients, along with increased coagulation, impaired fibrinolysis and endothelial dysfunction. Hyperglycaemia and insulin deficiency and resistance are suggested as important factors increasing platelet reactivity in these patients (25) .
Mean platelet volume is a parameter to assess platelet size, and is a potential marker of platelet reactivity. It has been shown that larger platelets are more active than smaller platelets (26) . Osmotic swelling owing to increased blood glucose and some glucose metabolites are suggested as possible mechanisms for an increased MPV in diabetic patients (27) .
There are several studies indicating the positive relationship between MPV and glycaemic indices, especially FBG and HbA1c (11, 12, 28) . On the other hand, some studies have shown that MPV is not related to FBG and HbA1c (8) (9) (10) 13) . Mean platelet volume is found to correlate with duration of diabetes in one study (9) , but not in another (13) . Therefore, it has been proposed that the increase in MPV is due to diabetic status alone (10) .
In our study, MPV in diabetic patients was higher than in the non-diabetic control group as usually noted in the literature. Moreover, there was a positive correlation between MPV and FBG and HbA1c, but not between MPV and duration of DM and PBG. We found that MPV was significantly higher in patients with HbA1c > 7% compared to those with HbA1c ≤ 7%, which may indicate the importance of glycaemic control in platelet reactivity. Demirtunc et al reported that MPV significantly decreased after improved glycaemic control (12) . This is a very important result because (i) it suggests that the increase in MPV may be associated with osmotic swelling of platelets and not diabetic tive studies with larger samples are needed, especially to investigate the relationship between MPV and diabetic microvascular complications and their progression.
